Malignant hypertensive end stage renal disease

Overview

Malignant hypertensive end-stage renal disease (ESRD) represents a critical intersection of cardiovascular and renal pathology, often necessitating comprehensive palliative care to address both the physical and psychosocial aspects of the disease. The demographic shift towards an aging population, with projections indicating a 25% increase in individuals aged 65 years and older, underscores the growing importance of managing end-of-life (EOL) care preferences and practices effectively [PMID:23739666]. This demographic trend amplifies the need for tailored palliative care strategies that prioritize patient comfort, symptom management, and respect for individual treatment goals. Patients with malignant hypertension and ESRD face multifaceted challenges, including complex fluid imbalances, cardiovascular complications, and the psychological burden of chronic illness, all of which require a holistic approach to care.

Epidemiology

The epidemiology of malignant hypertensive ESRD highlights significant disparities and growing demands on healthcare systems globally. In Arab populations, systemic barriers such as language barriers, cultural misconceptions, and fears of stigmatization contribute to lower referral rates to palliative care services compared to Jewish populations, despite potentially greater clinical needs [PMID:41430611]. This disparity is particularly concerning given the projected increase in elderly populations, where Iran, for instance, anticipates a 14.5% rise in non-communicable disease (NCD) mortality over two decades, placing substantial strain on its healthcare infrastructure and necessitating expanded palliative care services [PMID:39257943].

Globally, palliative care research has seen a surge, with 87.1% of relevant articles indexed in major databases published after 2011, predominantly focusing on oncology [PMID:38308605]. However, the broader spectrum of chronic diseases, including ESRD, often receives less attention, despite the increasing prevalence among aging populations. In Canada, the longevity of its citizens is leading to a higher incidence of life-limiting conditions, emphasizing the urgent need for improved access to palliative care services [PMID:37572064]. Studies from Ethiopia further reveal that socioeconomic factors, such as lower educational status and income, correlate with poorer access to palliative care among older cancer patients, indicating systemic inequities that must be addressed [PMID:37158021]. These trends highlight the necessity for culturally sensitive, accessible, and comprehensive palliative care frameworks to meet the diverse needs of patients with malignant hypertensive ESRD.

Clinical Presentation

Patients with malignant hypertensive ESRD often present with a constellation of symptoms reflecting both their renal failure and advanced cardiovascular disease. Fluid balance disturbances are particularly notable, with studies showing significant differences in extracellular water (ECW), intracellular water (ICW), and ECW/ICW ratios between edematous and non-edematous patients, underscoring the importance of meticulous fluid assessment in managing symptoms and potentially influencing survival outcomes [PMID:31657649]. These fluid imbalances can exacerbate cardiovascular complications, leading to symptoms such as dyspnea, edema, and hypertension, which require careful monitoring and management.

Psychosocial aspects are equally critical. Advanced cancer patients frequently experience unmet palliative care needs, with 81% of presentations involving unmet needs in advanced cancer cases and 77% in other EOL conditions [PMID:35119311]. Depression and strained caregiver relationships are significant predictors of a desire for hastened death, highlighting the emotional toll on both patients and their caregivers [PMID:16472040]. Additionally, the presence of hypermagnesemia in 23.08% of end-stage cancer patients underscores the need for vigilant electrolyte monitoring [PMID:33040566]. These clinical presentations emphasize the importance of a multidisciplinary approach that integrates medical management with psychological and social support to address the holistic needs of patients.

Diagnosis

Diagnosing malignant hypertensive ESRD involves a comprehensive evaluation of renal function, blood pressure control, and cardiovascular status. Key diagnostic criteria include persistent hypertension unresponsive to conventional therapy, evidence of renal impairment (e.g., elevated serum creatinine, decreased glomerular filtration rate), and signs of end-organ damage such as left ventricular hypertrophy or retinopathy. Early recognition of these markers is crucial for timely intervention and referral to palliative care services. However, evidence specifically tailored to the diagnostic criteria and clinical pathways for malignant hypertensive ESRD is limited, suggesting a need for more focused research in this area.

Management

The management of malignant hypertensive ESRD in the palliative care context requires a multifaceted approach that balances symptom control with respect for patient autonomy and preferences. Cultural and linguistic barriers significantly impact access to palliative care services, particularly among Arab populations, necessitating culturally sensitive training for healthcare providers to facilitate smoother referrals [PMID:41430611]. Effective communication about advanced care planning and patient preferences remains a critical gap, with many patients experiencing care that does not align with their goals [PMID:41310558].

Aggressive end-of-life care practices, such as intensive chemotherapy or radiotherapy, are common despite evidence suggesting they may not improve quality of life and can lead to increased hospitalizations and emergency interventions [PMID:41310558]. Tailoring treatment to individual patient goals is essential. Pharmacists play a pivotal role in palliative care, managing medication regimens, deprescribing unnecessary drugs, and focusing on symptom control like pain management and constipation relief [PMID:37291601]. Their involvement in compounding medications and providing direct patient care can significantly enhance symptom management and patient comfort.

Home-based care is increasingly favored by patients but often faces implementation challenges, particularly in regions like Iran where robust home-based palliative care infrastructure is lacking [PMID:39257943]. Ensuring that patients' preferences for place of care and death are respected requires proactive planning and coordination among healthcare providers, families, and palliative care teams. Advance care planning documents, such as DNR orders and living wills, are crucial for guiding clinical decisions and ensuring care aligns with patient wishes [PMID:34474810].

Prognosis & Follow-up

The prognosis for patients with malignant hypertensive ESRD is generally poor, with a focus shifting towards maintaining quality of life and comfort rather than curative treatment. Studies indicate that aggressive treatments like molecular targeted therapies and immunotherapies near EOL can lead to adverse outcomes, including increased hospitalizations and diminished quality of life [PMID:40377438]. Monitoring and managing fluid balance, particularly ICW levels, can inform personalized care approaches that may positively impact survival and symptom management [PMID:31657649].

Early recognition and proactive integration of palliative care can significantly improve outcomes. For instance, patients with documented advance care planning (ACP) 30+ days before death exhibit lower odds of in-hospital death, hospitalization, and ICU admissions [PMID:32181689]. Regular follow-up evaluations are essential to monitor overall well-being and adjust care plans accordingly, ensuring that patients experience the best possible quality of life and dignified death [PMID:34474810]. Retrospective studies highlight delays in EOL recognition, with only 17.1% of elderly patients in England recognized for EOL care more than a year before death, underscoring the need for earlier intervention and anticipatory guidance [PMID:33139331].

Special Populations

Arab Populations

Elderly Populations

Socioeconomic Disparities

Key Recommendations

References

1 Natour Hleihel N, Sperling D. Frames of dying: a qualitative study of end-of-life experiences of terminal Arab patients. BMC palliative care 2025. link 2 Wong WJ, Hwong WY, Teoh CCO, McCarthy SA, Subramaniam Kalianan R, Ng CJ. Stakeholder consensus of quality indicators for end-of-life cancer care in Malaysia: a modified Delphi study. BMC palliative care 2025. link 3 Barak R, Safadi E, Nikolaevski-Berlin A, Soback N, Wolf I, Waissengrin B. Systemic anticancer therapy at the end of life: real-world insights from a tertiary oncology center in Israel. The oncologist 2025. link 4 Barasteh S, Parandeh A, Rassouli M, Zaboli R, Vahedian Azimi A, Khaghanizadeh M. Future scenarios of palliative care in health system of Iran: a multi-method study. Frontiers in public health 2024. link 5 Cuchet I, Dambrun M, Bedhomme S, Savanovitch C, Roussel HV, Maneval A. The roles of French community pharmacists in palliative home care. BMC palliative care 2024. link 6 Dooms M. Pharmacists are initiators in palliative care for patients with rare diseases. Orphanet journal of rare diseases 2023. link 7 Crawford GB, Dzierżanowski T, Hauser K, Larkin P, Luque-Blanco AI, Murphy I et al.. Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines. ESMO open 2021. link 8 Stow D, Matthews FE, Hanratty B. Timing of GP end-of-life recognition in people aged ≥75 years: retrospective cohort study using data from primary healthcare records in England. The British journal of general practice : the journal of the Royal College of General Practitioners 2020. link 9 McDermott CL, Engelberg RA, Sibley J, Sorror ML, Curtis JR. The Association between Chronic Conditions, End-of-Life Health Care Use, and Documentation of Advance Care Planning among Patients with Cancer. Journal of palliative medicine 2020. link 10 Amano K, Liu D, Bruera E, Hui D. Collapse of Fluid Balance and Association with Survival in Patients with Advanced Cancer Admitted to a Palliative Care Unit: Preliminary Findings. Journal of palliative medicine 2020. link 11 Hirvonen OM, Alalahti JE, Syrjänen KJ, Jyrkkiö SM. End-of-life decisions guiding the palliative care of cancer patients visiting emergency department in South Western Finland: a retrospective cohort study. BMC palliative care 2018. link 12 Lee Y, Lee SH, Kim YJ, Lee SY, Lee JG, Jeong DW et al.. Effects of a new medical insurance payment system for hospice patients in palliative care programs in Korea. BMC palliative care 2018. link 13 Zhang B, Wright AA, Huskamp HA, Nilsson ME, Maciejewski ML, Earle CC et al.. Health care costs in the last week of life: associations with end-of-life conversations. Archives of internal medicine 2009. link 14 Elamri N, Atif I, Lyazidi A, Rattal M, Gantar A. Bibliometric analysis on palliative care in Morocco. International journal of palliative nursing 2024. link 15 Reason B, Paltser G. Access to Palliative Care in Canada. Healthcare quarterly (Toronto, Ont.) 2023. link 16 Aynalem A, Abdella Muhammed J, Taylor L, Unverzagt S, Kroeber ES, Deribe B et al.. Utilization of palliative care and its associated factors among adult cancer patients in Hawassa University comprehensive specialized hospital oncology center, Hawassa, Ethiopia, 2021: a cross-sectional study. Current medical research and opinion 2023. link 17 Kirkland SW, Yang EH, Clua MG, Kruhlak M, Villa-Roel C, Elwi A et al.. Comparison of the Management and Short-Term Outcomes between Patients with Advanced Cancer and Other End-of-Life Conditions Presenting to Two Canadian Emergency Departments. Journal of palliative medicine 2022. link 18 Takahashi M, Uchino N. Risk factors of hypermagnesemia in end-stage cancer patients hospitalized in a palliative care unit. Annals of palliative medicine 2020. link 19 Mack DS, Dosa D. Improving Advanced Care Planning through Physician Orders for Life-Sustaining Treatment (POLST) Expansion across the United States: Lessons Learned from State-Based Developments. The American journal of hospice & palliative care 2020. link 20 Slipka AF, Monsen KA. Toward Improving Quality of End-of-Life Care: Encoding Clinical Guidelines and Standing Orders Using the Omaha System. Worldviews on evidence-based nursing 2018. link 21 Khan RI. Palliative care in Pakistan. Indian journal of medical ethics 2017. link 22 Kovacević A, Dragojević-Simić V, Rancić N, Jurisević M, Gutzwiller FS, Matter-Walstra K et al.. End-of-life costs of medical care for advanced stage cancer patients. Vojnosanitetski pregled 2015. link 23 Krongyuth P, Campbell CL, Silpasuwan P. Palliative care in Thailand. International journal of palliative nursing 2014. link 24 Fowler R, Hammer M. End-of-life care in Canada. Clinical and investigative medicine. Medecine clinique et experimentale 2013. link 25 Walker H, Anderson M, Farahati F, Howell D, Librach SL, Husain A et al.. Resource use and costs of end-of-Life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. Journal of palliative care 2011. link 26 Ransom S, Sacco WP, Weitzner MA, Azzarello LM, McMillan SC. Interpersonal factors predict increased desire for hastened death in late-stage cancer patients. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 2006. link

26 papers cited of 53 indexed.